Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate diagnosis, resolving families’ long search for answers. Our goal is to radically change the field of pediatric genomic medicine by enabling the integration of genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.
Claritas was spun out of Boston Children’s Hospital in 2013 to become a world-class, commercial genetic diagnostic business and is now located in Cambridge, MA. At the outset, our strategic investors included Cincinnati Children’s Hospital Medical Center, Thermo Fisher (original investment from Life Technologies), and Cerner Corporation. WuXi-NextCODE became an investor in 2014.
Today, we are more than a genetic testing laboratory. By combining the clinical expertise of the world’s best pediatric specialists with innovative solutions to bioinformatics, reporting, and collaborative data sharing, we believe we will not only improve patient care, but also enable new discoveries to advance the field.
Offering a wide array of genetic diagnostic testing and research from single gene disorders to whole exomes, Claritas serves a customer base of over 100 hospitals and medical centers. We are committed to the highest quality and accessibility of information; our interpretative services and unique approach to reporting set the standard for reliably and clearly communicating genetic information. Striving for scientific excellence, we use trusted and innovative technology to maximize the sensitivity and accuracy of patient results. We call our 21st Century approach to genomic medicine The Claritas Experience.